Factor XI deficiency diagnosed following use of adalimumab

Adalimumab is a drug used in the treatment of refractory psoriasis. We present a case of a 55-year-old male patient who developed petechiae and purpura after the ninth dose of adalimumab therapy. The results of laboratory investigations revealed factor XI (F.XI) deficiency. It should be recognized t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cetin, Guven, Karatoprak, Cumali, Kiskac, Muharrem, Zorlu, Mehmet, Rezvani, Aylin, Cikrikcioglu, Mehmet Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Drug Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175897/
https://www.ncbi.nlm.nih.gov/pubmed/25298590
http://dx.doi.org/10.4103/0253-7613.140596
Descripción
Sumario:Adalimumab is a drug used in the treatment of refractory psoriasis. We present a case of a 55-year-old male patient who developed petechiae and purpura after the ninth dose of adalimumab therapy. The results of laboratory investigations revealed factor XI (F.XI) deficiency. It should be recognized that F XI deficiency may develop in patients using long-term adalimumab, leading to increased risk of bleeding.

Ejemplares similares